Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

  • C. Colin
  • P. Vergnon
  • A. M. Jullien
  • S. Excoffier
  • Y. Matillon
  • C. Trepo
  • J. P. Aymard
  • D. Bastit
  • M. L. Bidet
  • R. Breviere
  • F. Chenais
  • F. Hau
  • D. Houssay
  • A. Mercadier
  • P. Maisonneuve
  • M. Lambert
  • C. Waller
  • D. Boudart
  • C. Cotte
  • M. H. Elghouzzi
  • C. Janot
  • M. Daudet
  • M. Menault
  • M. Montcharmont
  • W. Smilovici
  • C. Fretz
  • R. Follana
  • M. Doillon
  • J. C. Le Petit
  • P. Herve
  • B. Loyer
  • B. Mattlinger
Article

DOI: 10.1007/BF01709585

Cite this article as:
Colin, C., Vergnon, P., Jullien, A.M. et al. Eur. J. Clin. Microbiol. Infect. Dis. (1997) 16: 220. doi:10.1007/BF01709585
  • 43 Downloads

Abstract

The current approach to screening for hepatitis C and non-A, non-B, non-C hepatitis in French blood transfusion centers involves a combination of a transaminase assay and tests for antibodies to hepatitis B core antigen (anti-HBc) and antibodies to hepatitis C virus (anti-HCV). A decision-analysis model was used to assess the cost-effectiveness ratio of this approach compared to the former approach, which included only transaminase and anti-HBc screening. Cost data were collected by a questionnaire sent to 26 centers throughout France. The average costs of diagnostic kits, equipment, staff, and administration were calculated. Estimates of prevalence and sensitivity values came from the medical literature. The cost-effectiveness ratio was expressed in French francs per infected donor detected. A sensitivity analysis of the variables in the model was performed to estimate the validity of the cost-effectiveness ratio. For 100,000 donations the incremental cost of the current approach reached FrF 2,566,111 (about US $ 500,000), with a marginal effectiveness of 180 donations detected. The sensitivity analysis showed the effect of prevalence on the incremental cost-effectiveness ratio. Transfusion centers may change their screening approach in areas of high or low prevalence of hepatitis C in France.

Copyright information

© MMV Medizin Verlag GmbH 1997

Authors and Affiliations

  • C. Colin
    • 1
  • P. Vergnon
    • 1
  • A. M. Jullien
    • 2
  • S. Excoffier
    • 1
  • Y. Matillon
    • 1
  • C. Trepo
    • 3
  • J. P. Aymard
    • 4
  • D. Bastit
    • 5
  • M. L. Bidet
    • 6
  • R. Breviere
    • 7
  • F. Chenais
    • 8
  • F. Hau
    • 9
  • D. Houssay
    • 10
  • A. Mercadier
    • 11
  • P. Maisonneuve
    • 12
  • M. Lambert
    • 13
  • C. Waller
    • 14
  • D. Boudart
    • 15
  • C. Cotte
    • 16
  • M. H. Elghouzzi
    • 17
  • C. Janot
    • 18
  • M. Daudet
    • 19
  • M. Menault
    • 20
  • M. Montcharmont
    • 21
  • W. Smilovici
    • 22
  • C. Fretz
    • 23
  • R. Follana
    • 24
  • M. Doillon
    • 25
  • J. C. Le Petit
    • 26
  • P. Herve
    • 27
  • B. Loyer
    • 28
  • B. Mattlinger
    • 29
  1. 1.Département d'Information Médicale des Hospices Civils de LyonHÔtel-DieuLyon Cedex 02France
  2. 2.HÔpital Saint AntoineCentre de Transfusion SanguineParisFrance
  3. 3.Unité INSERM 271LyonFrance
  4. 4.European Acute Transfusion Hepatitis Interferon Study-EconomicsMetz
  5. 5.European Acute Transfusion Hepatitis Interferon Study-EconomicsBois Guillaume
  6. 6.European Acute Transfusion Hepatitis Interferon Study-EconomicsAngers
  7. 7.European Acute Transfusion Hepatitis Interferon Study-EconomicsLille
  8. 8.European Acute Transfusion Hepatitis Interferon Study-EconomicsLa Tronche Grenoble
  9. 9.European Acute Transfusion Hepatitis Interferon Study-EconomicsBordeaux
  10. 10.European Acute Transfusion Hepatitis Interferon Study-EconomicsAnnecy
  11. 11.European Acute Transfusion Hepatitis Interferon Study-EconomicsBobigny
  12. 12.European Acute Transfusion Hepatitis Interferon Study-EconomicsLe Chesnay
  13. 13.European Acute Transfusion Hepatitis Interferon Study-EconomicsParis-Kremlin BicÊtre
  14. 14.European Acute Transfusion Hepatitis Interferon Study-EconomicsStrasbourg
  15. 15.European Acute Transfusion Hepatitis Interferon Study-EconomicsNantes
  16. 16.European Acute Transfusion Hepatitis Interferon Study-EconomicsMarseille
  17. 17.European Acute Transfusion Hepatitis Interferon Study-EconomicsRungis
  18. 18.European Acute Transfusion Hepatitis Interferon Study-EconomicsVandoeuvre les Nancy
  19. 19.European Acute Transfusion Hepatitis Interferon Study-EconomicsMontpellier
  20. 20.European Acute Transfusion Hepatitis Interferon Study-EconomicsSaint Brieux
  21. 21.European Acute Transfusion Hepatitis Interferon Study-EconomicsLyon
  22. 22.European Acute Transfusion Hepatitis Interferon Study-EconomicsToulouse
  23. 23.European Acute Transfusion Hepatitis Interferon Study-EconomicsParis-Pitié Salpétrière
  24. 24.European Acute Transfusion Hepatitis Interferon Study-EconomicsSaint Laurent du Var
  25. 25.European Acute Transfusion Hepatitis Interferon Study-EconomicsVienne
  26. 26.European Acute Transfusion Hepatitis Interferon Study-EconomicsSaint Etienne
  27. 27.European Acute Transfusion Hepatitis Interferon Study-EconomicsBesanÇon
  28. 28.European Acute Transfusion Hepatitis Interferon Study-EconomicsChambéry
  29. 29.European Acute Transfusion Hepatitis Interferon Study-EconomicsParis-NeckerFrance